These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 36757612)
1. NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease. Han QQ; Le W Neurosci Bull; 2023 May; 39(5):832-844. PubMed ID: 36757612 [TBL] [Abstract][Full Text] [Related]
2. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease. Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T Front Immunol; 2021; 12():719807. PubMed ID: 34691027 [TBL] [Abstract][Full Text] [Related]
3. Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease. Haque ME; Akther M; Jakaria M; Kim IS; Azam S; Choi DK Mov Disord; 2020 Jan; 35(1):20-33. PubMed ID: 31680318 [TBL] [Abstract][Full Text] [Related]
5. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective. Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624 [TBL] [Abstract][Full Text] [Related]
6. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Wang S; Yuan YH; Chen NH; Wang HB Int Immunopharmacol; 2019 Feb; 67():458-464. PubMed ID: 30594776 [TBL] [Abstract][Full Text] [Related]
7. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease. Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303 [TBL] [Abstract][Full Text] [Related]
8. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q Front Immunol; 2021; 12():794770. PubMed ID: 34925379 [TBL] [Abstract][Full Text] [Related]
10. Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic Considerations. Nguyen LTN; Nguyen HD; Kim YJ; Nguyen TT; Lai TT; Lee YK; Ma HI; Kim YE J Parkinsons Dis; 2022; 12(7):2117-2133. PubMed ID: 35988226 [TBL] [Abstract][Full Text] [Related]
11. From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease? Si XL; Fang YJ; Li LF; Gu LY; Yin XZ; Jun-Tian ; Yan YP; Pu JL; Zhang BR Exp Neurol; 2021 Feb; 336():113525. PubMed ID: 33161049 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1/Parkin pathway. Wang A; Zhong G; Ying M; Fang Z; Chen Y; Wang H; Wang C; Liu C; Guo Y Neuropharmacology; 2024 Oct; 257():110063. PubMed ID: 38972372 [TBL] [Abstract][Full Text] [Related]
13. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease. Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016 [TBL] [Abstract][Full Text] [Related]
14. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome. Kou L; Chi X; Sun Y; Han C; Wan F; Hu J; Yin S; Wu J; Li Y; Zhou Q; Zou W; Xiong N; Huang J; Xia Y; Wang T J Neuroinflammation; 2022 Jun; 19(1):133. PubMed ID: 35668454 [TBL] [Abstract][Full Text] [Related]
16. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities. Çınar E; Tel BC; Şahin G Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436 [TBL] [Abstract][Full Text] [Related]